The Real Cardiovascular Risks of Menopause: What Every Woman Needs to Know

Dr. Haver describes the standard approach to Lp(a) as a dangerous oversimplification for women. Because cardiology research was built on male cohorts where Lp(a) is predominantly genetically determined and stable, guidelines suggest a single measurement suffices. However, the European Heart Journal article and her clinical experience show that menopause triggers a significant upswing in Lp(a) for many women. She reports that she routinely sees patients whose Lp(a) and LDL were normal pre-menopause suddenly spike, leaving them unprotected by a normal earlier result. The failure to re-measure plus the fact that women with elevated Lp(a) are less likely to be prescribed statins and more likely to have side effects creates a perfect storm of under-treatment. She advocates annual monitoring of lipids with Lp(a) and ApoB to capture these changes early, enabling lifestyle and pharmacological interventions before plaque accumulates.

Dr. Haver argues that waiting until a woman meets criteria for diabetes is a missed opportunity, because the years of borderline blood sugars are silently damaging blood vessels. In her clinic, she routinely orders fasting insulin and glucose on every patient and computes HOMA-IR. She notes that women with insulin resistance have higher baseline inflammation and endothelial dysfunction, and that once diabetes is diagnosed, the cardiovascular risk is 25-50% higher in women than in men with the same condition. By screening early, she can aggressively deploy diet, exercise, and sometimes metformin or earlier GLP-1 therapy to reverse the metabolic trajectory. She stresses that patients can run the HOMA-IR themselves using a freely available online calculator, empowering them even if their doctor won't order it.

Dr. Haver highlights the article's recommendation that CAC scoring should be employed earlier and more liberally in women, given that only one in four women under 50 has ever had one. Because women's heart disease often manifests as microvascular dysfunction or diffuse non-obstructive plaque, a CAC scan may not be perfect, but it remains a powerful tool to detect the calcific subset. She shares that she pays out of pocket for tests that insurance won't cover because knowing her risk is worth it. She also points out the synergy with mammography: breast arterial calcifications on mammogram should immediately lead to a CAC scan. This shifts the paradigm from a single issue cancer screen to a cardiovascular sentinel.

Dr. Haver stresses that the article is unequivocal: pregnancy complications must be documented as cardiovascular events. The physiological stress of pregnancy—massive increases in blood volume, cardiac output, and metabolic demand—uncovers a woman's vascular vulnerability. Preeclampsia, for example, shares pathophysiological features with atherosclerosis, including endothelial dysfunction and inflammation. Yet after delivery, women are typically discharged with no long-term cardiovascular follow-up plan. She advises women to keep their own records and, if they have any of these markers, to triple down on the risk factors they can control: diet, exercise, sleep, blood pressure control, lipid management, and never smoking. She uses herself as an example: she has a history of PCOS and infertility (another hit), so she is personally motivated to optimize her modifiable factors.

Dr. Haver and her clinic use testosterone extensively but with a strict “low and slow” philosophy. She warns that commercially available pellet therapies from companies like BioTE typically deliver male doses that push women's testosterone into the hundreds, dramatically increasing side effect rates. She explicitly calls the lack of female physiologic dosing in pellets a red flag and urges women to run from providers offering only pellets. Instead, she prescribes transdermal gels and monitors levels and side effects closely. The irreversible effects—voice deepening and clitoromegaly—are highlighted because she has seen cases. She balances this by sharing her own positive experience: testosterone significantly helped her libido, illustrating that when done correctly, it can be life-enhancing.

Dr. Haver learned from her podcast guest Dr. Andrea Matsumura that snoring is never a cute, benign quirk in women—it is a critical warning sign. Women are often excluded from the stereotypical picture of sleep apnea (obese, middle-aged, male, loud snorer), so they are rarely screened. The consequence is that women with apnea are left untreated, facing a 4x higher cardiovascular mortality risk, plus contributions to atrial fibrillation, hypertension, and heart failure with preserved ejection fraction—a subtype that overwhelmingly affects women. She stresses that the new article explicitly recognizes poor sleep and sleep apnea as cardiovascular risk factors, and that because sleep deprivation also uniquely raises inflammatory cytokines in women, the combination is a double hit.

Dr. Haver reassures a viewer that this is very common and typically self-limited. Her clinical algorithm is to first increase progesterone because it provides endometrial protection and often stops the bleeding. If that fails, she reduces the estrogen, though that might sacrifice symptom relief. For difficult cases, she uses a levonorgestrel IUD to locally deliver progestin without systemic side effects, or switches to Duavee, which contains bazedoxifene, a SERM that blocks estrogen receptors in the uterus and breast. This approach allows women to continue benefiting from estrogen while minimizing bleeding and potential risks. She emphasizes that it's rarely due to anything malignant, but women deserve a clinician who will troubleshoot with nuance.

Dr. Haver highlights that the article explicitly calls out the belief that Lp(a) doesn’t change as a “lie” when applied to women. She reports seeing this pattern in her own clinic: patients who had never had cholesterol issues before menopause suddenly show dramatic increases in both LDL and Lp(a). The implication is that women who were told their single Lp(a) test was fine may now be walking around with a high-risk profile that no one would suspect. She insists that every woman should have Lp(a) checked at least once, then again after menopause, to capture this potential rise. The failure to do so leaves women underdiagnosed and undertreated, contributing to the higher cardiovascular mortality they face compared to men with similar standard risk scores.

Dr. Haver recounts that researchers are exploring this particle as a screening test for perimenopause because it does not rise with age alone—only with the hormonal changes of menopause. She finds it fascinating that women’s lipid metabolism undergoes such a dramatic, specific shift that could be captured in a standard blood test. This could simultaneously identify women entering the high-risk cardiovascular transition and prompt early intervention with diet, exercise, and possibly lipid-lowering therapy. She emphasizes that current testing paradigms miss this entirely because they lump all LDL together and ignore the subset.

Dr. Haver bluntly states that if a mammogram reveals microcalcifications in the breast arteries, it is highly likely that similar calcification is occurring in the coronary arteries. She sees this as a wasted early warning system because neither radiologists nor primary care providers routinely inform patients of the cardiovascular implications. She advises women to actively request a coronary artery calcium (CAC) score if their mammogram mentions vascular calcifications. This shifts the mammogram from a single-purpose cancer screen to a dual-purpose cardiovascular risk assessor, potentially catching heart disease years before symptoms appear.

Dr. Haver underscores that poor sleep is now officially recognized as a cardiovascular risk factor, but the sex difference makes it even more urgent for women. In her clinical practice, she tracks hs-CRP in all patients as a non-specific inflammation marker, and she sees it as a powerful tool to motivate lifestyle changes. The fact that IL-6 and CRP are elevated by poor sleep exclusively in women means that the sleep disruption so common in perimenopause and menopause (due to hot flashes, hormonal shifts, and aging) directly fuels the vascular inflammation that leads to atherosclerosis. She also notes that sleep apnea is massively underdiagnosed in women because we tend not to snore loudly, and untreated apnea increases cardiovascular mortality nearly fourfold.

Dr. Haver reads directly from the article that women’s cardiovascular risk is underestimated by 31 to 81% when using current calculators because these tools ignore pregnancy complications (preeclampsia, gestational diabetes, preterm birth), irregular menstrual cycles, autoimmune conditions, and early menopause. She argues this is a catastrophic gap that leaves women undiagnosed and untreated until they have a heart attack. The calculators create a false sense of security, so women and their doctors don't pursue advanced screening like CAC scans or aggressive lipid management. She insists that a new, women-validated risk calculator is urgently needed, but in the meantime, women must self-advocate by knowing their own reproductive and autoimmune history and demanding earlier imaging.